Jazz Pharmaceuticals Officer Files Form 144 for $1.5M Planned Sale

Executive Summary

On September 1, 2026, Bruce C Cozadd, an Officer of Jazz Pharmaceuticals plc ($JAZZ), submitted a Form 144 filing disclosing an intent to sell 6,000 shares of common stock through broker Merrill Lynch, representing an aggregate market value of approximately $1,500,780 (~$250.13 per share).

Transaction & Plan Details

• Securities to be Sold: 6,000 Common shares acquired via stock option exercises in February and March 2018.
• 10b5-1 Plan Adoption: The transaction is executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on November 26, 2025.
• Recent Past Sales: The insider has executed recurring monthly sales of 6,000 shares each over the past three months:
  • August 3, 2026: 6,000 shares for $1,517,880
  • July 1, 2026: 6,000 shares for $1,442,820
  • June 1, 2026: 6,000 shares for $1,410,720

Trading Significance Assessment

• Impact: Low
• Context: The proposed sale represents a fraction (~0.009%) of the 64,914,577 common shares outstanding. Given the recurring monthly cadence under an established Rule 10b5-1 trading plan adopted in late 2025, this filing represents standard executive diversification rather than a discretionary market-timing signal.